Aveanna Healthcare (NASDAQ:AVAH) Price Target Raised to $14.00 at BMO Capital Markets

Aveanna Healthcare (NASDAQ:AVAH) had its price objective boosted by BMO Capital Markets from $10.00 to $14.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price would suggest a potential upside of 24.00% from the stock’s current price.

AVAH has been the topic of several other reports. Barclays lifted their price target on Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Stephens raised shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $10.00 to $11.00 in a research note on Friday, May 15th. Truist Financial boosted their target price on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Royal Bank Of Canada raised shares of Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, June 3rd. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.22.

Aveanna Healthcare Price Performance

Shares of AVAH opened at $11.29 on Friday. Aveanna Healthcare has a one year low of $5.93 and a one year high of $11.54. The stock’s fifty day moving average is $8.86 and its 200-day moving average is $7.73. The company has a debt-to-equity ratio of 5.35, a quick ratio of 1.47 and a current ratio of 1.47. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of 9.57, a price-to-earnings-growth ratio of 0.90 and a beta of 1.90.

Aveanna Healthcare (NASDAQ:AVAH) last announced its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.03. The firm had revenue of $670.48 million during the quarter, compared to analyst estimates of $638.61 million. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%. Equities analysts anticipate that Aveanna Healthcare will post 0.68 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder J.H. Whitney Equity Partners V sold 2,419,035 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $8.01, for a total transaction of $19,376,470.35. Following the completion of the sale, the insider directly owned 10,112,123 shares of the company’s stock, valued at $80,998,105.23. This represents a 19.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Paul R. Vigano sold 3,000,000 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $8.01, for a total value of $24,030,000.00. Following the completion of the transaction, the insider owned 190,130 shares of the company’s stock, valued at $1,522,941.30. This trade represents a 94.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 31,305,664 shares of company stock valued at $215,555,910. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Aveanna Healthcare during the second quarter valued at approximately $63,504,000. Vanguard Group Inc. boosted its stake in Aveanna Healthcare by 38.0% in the 4th quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock worth $45,564,000 after purchasing an additional 1,535,351 shares during the period. Millennium Management LLC boosted its stake in Aveanna Healthcare by 1,007.1% in the 4th quarter. Millennium Management LLC now owns 1,114,717 shares of the company’s stock worth $9,107,000 after purchasing an additional 1,014,030 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Aveanna Healthcare during the 2nd quarter worth approximately $7,881,000. Finally, Nuveen LLC grew its position in Aveanna Healthcare by 135.9% during the 4th quarter. Nuveen LLC now owns 1,571,308 shares of the company’s stock worth $12,838,000 after purchasing an additional 905,316 shares in the last quarter. 87.96% of the stock is owned by hedge funds and other institutional investors.

Aveanna Healthcare News Roundup

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Quarterly results exceeded expectations. Aveanna reported adjusted earnings of $0.22 per share, above consensus estimates of approximately $0.17–$0.19, while revenue reached $670.5 million versus the $638.6 million consensus estimate. Revenue increased 13.7% year over year, and net income rose to $40.3 million from $27.0 million. Aveanna Healthcare second-quarter financial results
• Positive Sentiment: Management raised its 2026 financial targets. Full-year revenue guidance was increased to more than $2.68 billion from $2.63 billion–$2.65 billion, while adjusted EBITDA guidance rose to more than $365 million from $338 million–$342 million. Adjusted EBITDA for the quarter was $95.4 million, up 8% year over year. Aveanna Healthcare earnings call highlights
• Positive Sentiment: Analyst commentary was supportive. One analysis said the results reinforced its buy rating, citing Aveanna’s relatively low forward valuation and strong EBITDA margin compared with peers. The company’s Private Duty Services segment remains the main growth engine, accounting for roughly 83% of revenue. Aveanna Healthcare Q2 earnings analysis
• Neutral Sentiment: Investors are focusing on execution and the earnings-call outlook. The strong growth forecast supports the recent rally, but the stock’s valuation and elevated leverage may make it more sensitive to any slowdown in operating performance or guidance.
• Negative Sentiment: Gross-margin pressure remains a concern. Despite revenue growth, gross margins declined across Aveanna’s business segments. Continued margin compression could limit the benefit of higher revenue and make the upgraded EBITDA targets harder to sustain. Aveanna Healthcare Q2 2026 earnings call transcript

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.